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Absract: We present a case with limited disease small cell lung
carcinoma with persisting disease and a troublesome syndrome of
inappropriate antidiuretic hormone, despite concurrent chemoradio-
therapy and second-line chemotherapy. To gain local control, a
lobectomy was performed.
Key Words: Small cell lung carcinoma, Mixed tumor, Carcinoid,
SIADH.
(J Thorac Oncol. 2009;4: 1291–1292)
CASE REPORT
A 54-year-old woman in good physical condition was
referred to our outpatient clinic for analysis of persisting
cough and dyspnea during exercise. Chest radiograph showed
an atelectasis of the right upper lobe (RUL), and at bronchos-
copy, the RUL was completely obstructed by tumor.
Biopsies showed a characteristic overview of small cell
lung carcinoma (SCLC; Figure 1A). The proliferation marker,
KI-67, was positive in about 40% of the tumor cells (Figure 1B).
Staging with computed tomography, FDG-positron
emission tomography scan, and magnetic resonance imaging
showed no signs of enlarged mediastinal lymph nodes, nor
distant or cerebral metastasis. Therefore, the final staging was
limited disease. At presentation, a syndrome of inappropriate
antidiuretic hormone (SIADH) was present and therefore a
fluid restriction was maintained.
Evaluation of response after concurrent chemoradiother-
apy showed a stable disease and a persisting SIADH. A second
bronchoscopy, along with biopsies, confirmed persistent SCLC.
After second-line chemotherapy with carboplatin and paclitaxel,
a partial response was obtained, although the SIADH remained
active. Restaging with FDG-positron emission tomography scan
and computed tomography scan still showed only local disease.
To gain local control, a sleeve lobectomy of the RUL
was performed together with a lobectomy of the middle lobe
and a mediastinal lymphadenectomy. Surprisingly, histologic
examination of the tumor showed a well-preserved organoid
tumor with a neuroendocrine signature (Figure 2A). This time
the fraction of KI-67 positive tumor cells was less than 5%
(Figure 2B). It was classified as an atypical carcinoid tumor,
which was radically resected. With 21 months of follow-up,
there are no signs of relapse.
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FIGURE 1. Small cell lung carcinoma. A, H&E staining
with small cells with a high nuclear-cytoplasmic ratio, hyper-
chromatic polymorphous nuclei and no or inconspicuous
nucleoli. In addition, numerous apoptotic cells. B, Ki-67
staining with about 40% of positive cells as a reflection of
the high mitotic rate. Typical for SCLC is that the Ki-67
marker is at least positive in 25% of the cells.3
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DISCUSSION
Some surgical series report a nonsmall cell lung cancer
(NSCLC) component in 11 to 15% after induction chemo-
therapy for SCLC.1,2 In our patient, a second bronchoscopy
was performed to answer this question.
Because of active disease after second-line chemother-
apy, the patient was referred for surgery. The Toronto group
showed that patients with relapsed or unresponsive limited
disease SCLC may obtain local control by surgery, provided
there are no signs of nodal disease. In their series, after
resection, 10 of 28 patients were found to have a mixed
histology or pure NSCLC. These patients achieved a median
survival of more than 2 years.2
The finding of an atypical carcinoid tumor surprised us.
Especially as it was the cause of persisting SIADH, some-
thing we could not find reported before.
Revision of the previous biopsies taken using bronchos-
copy led to no different pathologic conclusions. Helpful for
the differentiation of the different neuroendocrine tumors was
the use of the proliferation marker KI-67.3
In conclusion, nonresponsive tumor after therapy for
SCLC should, in our opinion, lead to pathologic re-evalua-
tion, as a mixed histology with persisting NSCLC, or as in
this case, an atypical carcinoid can be present. In case of
persisting SCLC without mediastinal disease or signs of distant
metastasis, long-term survival or local control can be obtained
by surgical resection.
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FIGURE 2. Atypical carcinoid. A, H&E staining with solid
sheets of cells grown in an organoid fashion separated by fi-
brous septa. The tumor cells have a high nuclear-cytoplasmic
ratio, hyperchromatic fine granular polymorphous nuclei, and
no or inconspicuous nucleoli. The mitosis index is 3/mm2 and
apoptotic cells are rare. B, Ki-67 staining with less than 5% of
positive cells, reflecting the relative low mitotic count.
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